The Munich-based biotech startup Irubis has received 1.3 million euros in funding under the EU's Horizon 2020 funding program. The European Innovation Council (EIC) single-project aims to develop a novel measurement system for the automated monitoring and control of manufacturing processes in the biopharmaceutical industry.
Irubis is known for its novel sample carrier for ATR infrared spectroscopyThis technology has been used in laboratory analysis for many years to analyze a wide variety of materials and substances. The Irubis sample carrier significantly reduces costs while ensuring better results.
Irubis develops measuring device for drug production
The Munich-based company is also developing a new measuring device that can be used to monitor and regulate the production of biopharmaceutical drugs. This process control enables higher yields, improved quality, and shortens the overall process development time.
With financial support from Horizon 2020, Irubis will bring this innovative process monitoring technology to market readiness. It is an optical measuring device based on infrared spectroscopy that can be used to continuously monitor and control nutrient concentrations in bioreactors. With the fresh capital from the EU program, the ten-person team will be further expanded and extensive test runs and collaborations with customers from the biopharmaceutical industry will be realized.
"The biopharmaceutical industry faces the major challenge of developing a vaccine against SARS-CoV-2 within a very short time and producing it in large quantities. This particularly highlights how important it is that biopharmaceuticals can be developed more quickly and cost-effectively so that they are available to patients. We are providing an important building block for this,"
explains co-founder and CTO Lorenz Sykora. And further:
"Through our close collaboration with industry, we work in a very customer-focused manner. Our goal is to offer a holistic solution for process monitoring and control."
